LBA6 PACIFIC-5: A phase III study of consolidation durvalumab (D) in patients (pts) with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy (cCRT or sCRT)

Yi‐Long Wu, Lin Wang, N. Bi et al.|Annals of Oncology|2024

Cited by 8